US Patent

US9770441 — Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

Method of Use · Assigned to Pfizer Inc · Expires 2035-08-31 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and methods for their preparation.

USPTO Abstract

The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.

Drugs covered by this patent

Vyndaqel (tafamidis) · Foldrx Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2524`	—	Vyndaqel

Patent Metadata

Patent number: US9770441
Jurisdiction: US
Classification: Method of Use
Expires: 2035-08-31
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.